Pharmaceutical Executive | Publications | Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and leadership to drive success.

Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in ...

Three years ago, when Pharmaceutical Executive last profiled Wendy Short Bartie, she was newly installed as senior vice ...

Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in obesity and diabetes care, and Wendy Short Bartie of Bristol Myers Squibb makes ...

Cellectis has announced that its board of directors have approved a strategic transformation to become an in vivo gene ...

Consolidation to a day-to-day “Novo” name seeks consistent global recognition while retaining Novo Nordisk A/S as the legal ...

Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing ...

Specifically, patients with high cortisol levels face unique challenges that GLP-1s may not be able to tackle. Dr. Elena Christofides: We have been doing a significant amount of medical education — ...

Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan ...

Novartis investors are placing increased pressure on Novartis’ dealmaking strategy after facing setbacks to drugs acquired ...

The health care industry has invested heavily in point solutions ($100 billion). We have one tool for scheduling, another for ...

GLP-1 medications might be most well-known as weight-loss options, but they were originally developed as a treatment for type 2 diabetes. For many patients, the drugs remain a highly effective ...